SB 9200 is a novel, first-in-class oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus, and influenza and has demonstrated activity against hepatitis B virus (HBV) in vitro and in vivo. In phase I clinical trials in chronically infected HCV patients, SB 9200 has been shown to reduce HCV RNA by up to 1.9 log 10 . Here, we demonstrate the antiviral activity of SB 9200 against a HCV replicon system and patient derived virus. Using the HCV capture-fusion assay, we show that SB 9200 is active against diverse HCV genotypes and is also effective against HCV derived from patients who relapse following direct-acting antiviral treatment, including viruses containing known NS5A resistance-associated sequences. These data confirm the broad antiviral activity of SB 9200 and indicate that it may have clinical utility in HCV patients who have failed to respond to current antiviral regimens.
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Mammalian cells have evolved a wide range of restriction factors to inhibit viral replication and protect the host from infection. Some of these factors are specific to viral families, such as TRIM5α 6 are drug concentrations at which a two-or a ten-fold depression of 
| Capture fusion assay
The capture fusion was performed as previously described with minor modifications. 16 THP-1 cells were seeded into six well plates values. Synergy studies were initiated by combining SB 9200 Combination studies of SB 9200 with other anti-HCV agents were carried out using the HCV genotype 1b CON1 sub-genomic replicons. All compounds were dissolved in DMSO to get 100 mM stock solution. Before initiating combination studies, the anti-HCV activity of individual compounds was determined using protocols described in the primary assays. Synergy studies were initiated by combining SB 9200 with each agent in different ratios based on individual EC 50 values to achieve equipotent anti-HCV activity of each combination.
a Synergy analysis using CalcuSynTM program (Biosoft, Inc.). 21 with each agent in different ratios based on individual EC 50 values to achieve equipotent anti-HCV activity of each combination (ratios remained constant throughout the dilution series).
Combination and monotherapy studies were conducted sideby-side with using 8, threefold dilutions to assess antiviral activity and drug interactions. In combination treatments with interferon alpha, ribavirin, or two different classes of anti-HCV direct-acting antiviral agents (nucleoside analogue, protease inhibitor), SB 9200 displayed predominantly synergistic interactions (Table 2 ).
FIGURE 1 SB 9200 demonstrates pan-genotypic antiviral activity against HCV. The sensitivity of patient derived HCV to SB 9200 was assessed in the phenotypic capture fusion assay. HCV-containing fused cells were treated with varying concentrations of SB 9200 and HCV RNA was quantified. Pooled results, normalized to untreated cells to account for variability in HCV RNA yield between samples from different donors are shown for each genotype (A-E) values are mean ± s.e.m. Comparison of the individual IC 50 for SB 9200 across the HCV genotypes tested (F) P-value (*P < 0.05) was calculated using Mann Whitney U-test
| SB 9200 demonstrates pan-genotypic antiviral activity against HCV
The capture fusion assay allows in vitro determination of the sensitivity of patient-derived HCV to antiviral drugs. The effect of SB 9200 on viral samples from a number of patients was determined (Patient details-supplementary Table S1 ). Cell viability in the capture fusion assay was not affected by the presence of SB 9200 (data not shown). Figure 1A -E shows the pooled 50% inhibitory concentration (IC 50 ) data for Genotypes 1,2,3,4, and 6. SB 9200 inhibited replication of all the genotypes tested in a dose-dependent manner. G3 isolates showed significantly greater sensitivity to SB 9200 than G1 strains (IC 50 0.035 ± 0.013 vs 0.22 ± 0.076, P = 0.048).
| Sensitivity of both G1 and G3 HCV to SB 9200 compares favorable to Alisporivir
The host-targeting agent, alisporivir, has been shown to be a potent in vitro inhibitor of HCV replication. 24 Using the capture fusion assay we assessed the antiviral activity of alisporivir against genotype 1 and 3 patient derived samples ( Fig. 2A,B ) (G1; IC 50 = 0.099 μM, G3; IC 50 = 0.036 μM). No significant difference was seen between the effect of alisporivir and SB 9200 on either G1 or G3 patient derived HCV (Fig. 2C,D) .
| SB 9200 shows activity against HCV variants derived from patients who have relapzed after IFN based therapy
Prior to the introduction of all oral antiviral therapy, interferon was widely used to treat HCV infection and patient response was FIGURE 3 SB 9200 shows activity against HCV derived from patients who have relapsed after IFN based therapy. Capture fusion assay was performed with sera from patients who had relapsed after IFN based therapy. Comparison of the SB 9200 IC 50 between treatment naïve (g1 n = 5 and g3 n = 7) and treatment experienced (g1 n = 3 and g3 n = 4) revealed no significant difference between the groups dependent on both viral genotype and host factors. 25, 26 We examined the activity of SB 9200 against viral samples from patients who had failed to respond to interferon-based therapy. No significant difference in SB 9200 efficacy was found between treatment naïve and treatment experienced patients in either G1 or G3 (Fig. 3 ).
3.5 | SB 9200 shows activity against HCV derived from patients who have relapsed after DAA therapy HCV treatment has now progressed to highly effective IFN-free regimens. To evaluate if SB 9200 had a differential effect on viruses derived from patients who had failed all oral regimens, we studied nine G3 patients from the English early access programe who had been treated with sofosbuvir plus an NS5A inhibitor-containing regime (patient details are shown in Supplementary Table S2) . Serum from these patients with low levels of viraemia was limited. Therefore, we assessed drug sensitivity with a single concentration of the antiviral agent and determined sensitivity by calculating fold change in HCV RNA from the non-treated controls. SB 9200 demonstrated antiviral activity against both the SVR and NR samples (Fig. 4) . The fold change in the SVR samples was similar to the tested NS5A inhibitors. In the NR samples, counter-intuitively, although blunted, we showed antiviral activity of the NS5A inhibitors, suggesting that resistance to the NS5A inhibitors had not developed.
| SB 9200 is active against DAA-resistant HCV variants
To expand our analysis of the activity of SB 9200 against NS5A, we selectively examined the effect of SB 9200 in samples with known NS5A resistance associated substitutions (RAS). Samples and sequencing data from Gilead's sofosbuvir clinical trial programe were kindly supplied by Gilead Sciences (Foster City, CA). Table 3 shows the sensitivity of these viruses to SB 9200. In these G1a
FIGURE 4 SB 9200 shows activity against HCV derived from patients who have relapsed after DAA therapy. Capture fusion assay was performed with sera from G3 patients who had responded (A) or failed to respond (B) to DAA treatment. A single dose (0.1 μM) in quadruplicate of either Daclatasvir, Ledipasvir, or SB 9200 was used and the fold change for each drug ± s.e.m plotted K I90V K107T S131T I144V R176 K E181D A213T M226E A245T  N246 K D285E V296I A310G R311P V315I V326L R348Q L368V T370N A400S  G403D V410A Y413C T442A   L31M  0.0026   1a  4850952  A25S Q30H V37L T64A R78 K T99V K107T S131T T135A I144V E171D E181D M226V  A245T D248E V296I R308 K A310S R311P V315I V326L P347S R348R/Q S349P  L368V N392E P399S A400G G403A P405L V410A G439E T442A   Q30H  0.2143   1a  3019319  A25S Q30H V37L T64A R78 K T99V K107T S131T T135A I144V E171D E181D M226V  A245T D248E V296I R308 K A310S R311P V315I V326L P347S S349P L368V  N392E P399S A400G G403A P405L V410A G439E T442A   Q30H  0.046   1a  1420666  S1A L31M R78 K K107T S131T I144V E171D E181D G215R M226E K240R A245T  I280V D285E E293D A310G R311P V315I V326L R348Q T367S L368V T395A  G403V P405L V410A Y413C D441E   L31M  >10 1a 5933317 I8I/V F36L V37V/M S85S/N I121I/V S131T I144V E171D E181D A197T L199V A213T G215 K M226L A241G D285E V288V/M V296I V298T A310T R311P V315I R348 K/ Q T367S L368V I388I/V G390S T393M T395A S397P P401S V410A G439E D441G None 0.02043
The activity of SB 9200 against serum from g1a patients who subsequently failed sofosbuvir/ledipasvir treatment was evaluated. Sequencing analysis revealed the presence of several HCV variants associated with poor response to current NS5A inhibitors. SB 9200 demonstrated antiviral activity against the known NS5A RAVs L31M and Q30H.
samples with known NS5A RAS, SB 9200 was generally potent although one sample (with the L31M RAS) did have a reduced sensitivity to the drug.
3.7 | Activity of SB 9200 against pre-and post-relapse HCV variants in a patient with emerging NS5A resistance
Pre-and post-treatment-failure serum was available from a patient who failed to respond to 12 weeks SOF/DAC/RBV treatment. The patient's viral load initially fell on treatment but virological breakthrough and relapse occurred after week 8 on treatment.
Deep sequencing was performed on the serum pre-treatment and at week 20 after start of treatment. Analysis of the NS5A sequence showed that RASs, including those known to inhibit the activity of current NS5A inhibitors-S62L and Y93H-were present in the pretreatment samples and these were enriched following unsuccessful treatment (Fig. 5A ). No significant difference in the activity of SB 9200 against the pre- (Fig. 5B ) and post-treatment (Fig. 5C ) quasispecies was seen when evaluated by capture fusion, suggesting that SB 9200 retains activity against treatment emergent NS5A substitutions.
FIGURE 5 Activity of SB 9200 against pre and post-relapse HCV variants in a g3 DAA failure. A decline in viral load (A) was observed during treatment with SOF/DAC/RBV but the viral load rebounded 8 weeks after the end of the DAA therapy. Pre-treatment and postrelapse samples were subjected to high throughput viral genome sequencing. Despite enrichment for known NS5A RAS (L62 and H93) in the post-relapse sample no significant difference was seen in out phenotypic capture fusion assay in the IC 50 between pre-treatment (B) and post-relapse (C) for SB 9200 14 Here we have evaluated the activity of SB 9200 in samples from patients with potentially difficult to cure HCV.
To confirm the activity of SB 9200 against HCV in established assays we used the well-described HCV replicon system. The EC 50
values obtained for the individual compounds we tested compared favorably to those previously reported in the literature 27 and confirmed that SB 9200 does have potent antiviral activity in this model. However, the replicon assay does not allow an evaluation of patient derived viral samples and is sub-optimal for phenotyping studies. The "capture-fusion" model is a recently described assay that allows patient derived virus to be analyzed. 16 Although the assay is cumbersome and can only be applied to samples with a high concentration of virus (usually >10 5 IU/mL) it has the advantage of allowing studies on patient derived, drug resistant virus. In this study,
we have deployed the assay to analyze SB 9200 in a wide range of samples and potent antiviral activity is seen against nearly all the isolates studied. Although SB 9200 had pan-genotypic antiviral activity, we noted increased sensitivity among G3 isolates with a minority of G1 samples being relatively insensitive to the drug. Of importance, isolates from patients who had failed to respond to current treatment regimens were inhibited by SB 9200, suggesting that this drug may be a valuable option in patients requiring "rescue"
therapy. One g1a sample with a L31M RAS in the NS5a appeared to be refractory to the effects of SB 9200, no other known RAS were identified in the NS5A protein, however we cannot discount the presence of other mutations within this sample. Further work will be required to identify the mechanisms underlying these differences.
The observed anti-HCV activity of SB 9200 is supported by the mechanism of action (MOA) studies of SB 9200/SB 9000. The activation of both RIG-I and NOD2, and the induction of the IFN signalling cascade could result in the expression of IFNs, ISGs and antiviral cytokines all of which may play an important role in the antiviral activity of SB 9200/SB 9000.
It is pertinent to mention that in the classical HCV replicon cells, RIG-I signalling is reported to be impaired. The HCV NS3/4A protease has been shown to inhibit phosphorylation of IRF-3, which is a key transcriptional regulator of the IFN response, thereby abrogating the antiviral response to infection. 28, 29 The Huh7.5 cells used in this study 30 contain a mutation in the RIG-I gene which disrupts IRF-3 activation. Nevertheless, the observed antiviral activity of SB 9200 against the HCV replicon may be partly due to SB 9200-mediated rapid shuttling of RIG-I on dsRNA that displaces viral polymerase from dsRNA template thereby inhibiting viral replication. 31 Fusion of Huh7 derived cell lines with the RIG-I competent monocytes is thought to reconstitute RIG-I activity, and in these hybrid cells SB 9200 was found to be a potent inhibitor of HCV replication.
In summary, we find that the broad-spectrum antiviral agent SB 9200 shows activity against a wide range of HCV isolates, including those that are refractory to current antiviral agents. These data indicate that trials of SB 9200 in patients with resistant chronic HCV infection are warranted and this drug may play an important role in the global elimination of HCV by increasing treatment options for patients who have failed to respond to first-line therapies.
